Canaccord Genuity Maintains Buy on Castle Biosciences, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $60 to $40.
June 06, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains Buy rating on Castle Biosciences but lowers price target from $60 to $40.
The news directly mentions Castle Biosciences (CSTL) and the lowered price target by Canaccord Genuity. While the Buy rating is maintained, the reduced price target may cause mixed reactions among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100